ADCT — ADC Therapeutics SA Share News
0.000.00%
Last trade - 00:00- $138.64m
- $327.99m
- $81.36m
ADC Therapeutics SA expected to post a loss of 86 cents a share - Earnings Preview
Brief: Adc Therapeutics Says Announced Exclusive License With Mitsubishi Tanabe Pharma Corporation To Develop And Commercialize Zynlonta® In Japan
ADC Therapeutics SA reports results for the quarter ended in September - Earnings Summary
Brief: ADC Therapeutics SA Q3 Sales $13.1 Mln
ADC Therapeutics SA expected to post a loss of 92 cents a share - Earnings Preview
Brief: ADC Therapeutics Doses First Patient In Phase 1 Clinical Trial Of ADCT-901 In Advanced Solid Tumors
U.S. RESEARCH ROUNDUP-CF Industries Holdings, DXC Technology Co, Rackspace Technology
ADC Therapeutics rises as newly approved cancer drug brings in nearly $4 mln in sales
ADC Therapeutics SA reports results for the quarter ended in June - Earnings Summary
ADC Therapeutics SA expected to post a loss of 86 cents a share - Earnings Preview
NYSE ORDER IMBALANCE 295627.0 SHARES ON BUY SIDE
Brief: ADC Therapeutics Announces Encouraging Interim Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine Presented At The 16Th Annual International Conference On Malignant Lymphoma
Brief: ADC Therapeutics SA Files For Shelf Of Up To 5.6 Mln Shares
ADC Therapeutics SA reports results for the quarter ended in March - Earnings Summary
Brief: Adc Therapeutics Reports Q1 Loss Per Share $0.67
ADC Therapeutics SA expected to post a loss of 90 cents a share - Earnings Preview
Brief: Onco360 Selected By ADC Therapeutics To Be Exclusive Specialty Pharmacy Partner For ZYNLONTA
Brief: Adc Therapeutics Announces FDA Approval Of ZYNLONTA In Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
U.S. STOCKS ON THE MOVE-Alcoa Corp, Idera Pharma, Kiniksa Pharma